AlphaMark Advisors’s NovoCure NVCR Stock Holding History

AlphaMark Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-280	Closed	-$21K	–	685
2022 Q3	$21K	Buy	+280	New	+$21.8K	0.01%	313

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaMark Advisors's NVCR Position: Q4 2022 in Review

AlphaMark Advisors sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 280 shares — an estimated $21K sold.

AlphaMark Advisors first reported a position in NVCR in Q3 2022 and held it in 1 quarter. The position peaked at $21K in Q3 2022. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

AlphaMark Advisors reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
AlphaMark Advisors sold 280 NovoCure shares in Q4 2022, an estimated $21K.
AlphaMark Advisors first reported a position in NovoCure in Q3 2022 and held it in 1 quarter.
AlphaMark Advisors's NovoCure position peaked at $21K in Q3 2022.
304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on AlphaMark Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.